For more information on the presentation and on the procrastinators program, click here
Compare current Canadian prices Zepbound's $50/Month Medicare Pricing Now in Effect in the US A quick update on a story we've been tracking: Eli Lilly's agreement with the US government to offer Zepbound (tirzepatide) at no more than US$50/month for Medicare beneficiaries took effect this month, starting April 1, 2026
While its not a replacement for vaccines or standard medical care, some healthcare providers have explored its potential benefits in reducing the severity of symptoms
Arteriosclerosis, thrombosis and vascular biology 27, 20942099 (2007)
Research note: A 2025 literature and patent review catalogued BPC-157's multifunctional activity across gastrointestinal, musculoskeletal, neurological, and cardiovascular preclinical models